Markets

Here’s Why ImmunoGen Jumped 12.4% Today

What happened

Shares of ImmunoGen (NASDAQ: IMGN) closed Wednesday 12.4% higher as investors piled into the biotech ahead of the American Society of Hematology (ASH) Annual Meeting, which starts Saturday.http://investor.immunogen.com/news-releases/news-release-details/immunogen-present-new-data-imgn632-61st-ash-annual-meeting

So what

On Monday afternoon at ASH, ImmuoGen is scheduled to present data from an early-stage phase 1 clinical trial of IMGN632 in patients with two types of blood cancers: acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).

An abstract for the presentation released last month showed IMGN632 produced a 32% response rate in 19 patients with AML who were treated at the dose that will be used in the drug's phase 2 study. In patients with BPDCN, the response rate was even higher at 43%, although there were only seven evaluable patients.

The abstracts for ASH had to be submitted in early August, so presumably, ImmunoGen's presentation next week will have data from more patients, which could give investors more confidence that IMGN632 is truly active.https://www.hematology.org/Annual-Meeting/Abstracts/2853.aspx

Woman in a hospital bed holding hands with another woman

Image source: Getty Images.

Now what

ImmunoGen's investors could certainly use some good news after the phase 3 clinical trial failure of mirvetuximab soravtansine as a treatment for ovarian cancer. The company believes the drug will work in patients with tumors that express high levels of folate receptor alpha, the target of mirvetuximab, but that phase 3 clinical trial hasn't even started yet, so ImmunoGen is years away from getting that candidate drug on the market.

To help ensure it has the resources to get there, ImmunoGen is conserving the approximately $200 million in cash it had in the bank at the end of the third quarter. However, positive early-stage data for IMGN632 could help the biotech ease its cash concerns by either licensing the drug to a large-pharma partner or, if its valuation gets buoyed further, selling new shares via a secondary stock offering.

10 stocks we like better than ImmunoGen
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and ImmunoGen wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of June 1, 2019

 

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

IMGN

Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More